SEC Info - ChromaDex Corp. - ‘10-Q’ for 4/2/16

SEC Info℠

Home

Help

Please Sign In

ChromaDex Corp. – ‘10-Q’ for 4/2/16 – ‘EX-10.4’

On: Thursday, 5/12/16, at 6:21am ET · For: 4/2/16 · Accession #: 1415889-16-5829 · File #: 1-37752

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/12/16  ChromaDex Corp.                   10-Q        4/02/16   67:3.6M                                   SEC Connect

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    397K 
 2: EX-10.1     Supply Agreement                                    HTML     67K 
 3: EX-10.2     Supply Agreement                                    HTML     62K 
 4: EX-10.3     Amendment to Supply Agreement                       HTML     39K 
 5: EX-10.4     Addendum to the Niagen Supply Agreement             HTML     25K 
 6: EX-10.5     First Amendment to Niagen Supply Agreement          HTML     26K 
 7: EX-10.6     Second Amendment to Niagen Supply Agreement         HTML     35K 
 8: EX-31.1     Certification of the Chief Executive Officer        HTML     24K 
                Pursuant to 240.13A14 or 240.15D14 of the                        
                Securities Exchange Act of 1934, as Amended                      
 9: EX-31.2     Certification of the Chief Financial Officer        HTML     24K 
                Pursuant to 240.13A14 or 240.15D14 of the                        
                Securities Exchange Act of 1934, as Amended                      
10: EX-32.1     Certification Pursuant to 18 U.S.C. Section 1350    HTML     21K 
                (As Adopted Pursuant to Section 906 of the                       
                Sarbanesoxley Act of 2002)                                       
17: R1          Document and Entity Information                     HTML     45K 
18: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML     94K 
19: R3          Condensed Consolidated Balance Sheets (Unaudited)   HTML     33K 
                (Parenthetical)                                                  
20: R4          Condensed Consolidated Statements of Operations     HTML     73K 
                (Unaudited)                                                      
21: R5          Condensed Consolidated Statement of Stockholders'   HTML     56K 
                Equity (Unaudited)                                               
22: R6          Condensed Consolidated Statement of Stockholders'   HTML     22K 
                Equity (Parenthetical)                                           
23: R7          Condensed Consolidated Statements of Cash Flows     HTML    108K 
                (Unaudited)                                                      
24: R8          Interim Financial Statements                        HTML     24K 
25: R9          Nature of Business and Liquidity                    HTML     25K 
26: R10         Significant Accounting Policies                     HTML     27K 
27: R11         Reverse Stock Split                                 HTML     21K 
28: R12         Earnings Per Share Applicable to Common             HTML     37K 
                Stockholders                                                     
29: R13         Leasehold Improvements and Equipment                HTML     27K 
30: R14         Loan Payable                                        HTML     26K 
31: R15         Share-Based Compensation                            HTML     32K 
32: R16         Stock Issuance                                      HTML     29K 
33: R17         Warrants                                            HTML     32K 
34: R18         Business Segments                                   HTML     86K 
35: R19         Related-Party Transactions                          HTML     28K 
36: R20         Commitments and Contingencies                       HTML     25K 
37: R21         Significant Accounting Policies (Policy)            HTML     30K 
38: R22         Significant Accounting Policies (Tables)            HTML     24K 
39: R23         Earnings Per Share Applicable to Common             HTML     36K 
                Stockholders (Tables)                                            
40: R24         Leasehold Improvements and Equipment (Tables)       HTML     26K 
41: R25         Loan Payable (Tables)                               HTML     24K 
42: R26         Share-Based Compensation (Tables)                   HTML     29K 
43: R27         Stock Issuance (Tables)                             HTML     23K 
44: R28         Warrants (Tables)                                   HTML     32K 
45: R29         Business Segments (Tables)                          HTML     77K 
46: R30         Nature of Business and Liquidity (Details           HTML     29K 
                Narrative)                                                       
47: R31         Significant Accounting Policies (Details)           HTML     32K 
48: R32         Reverse Stock Split (Details Narrative)             HTML     24K 
49: R33         Earnings Per Share Applicable to Common             HTML     56K 
                Stockholders (Details)                                           
50: R34         Earnings Per Share Applicable to Common             HTML     22K 
                Stockholders (Details) (Details Narrative)                       
51: R35         Leasehold Improvements and Equipment (Details)      HTML     40K 
52: R36         Leasehold Improvements and Equipment (Details       HTML     22K 
                Narrative)                                                       
53: R37         Loan Payable - Loan payable (Details)               HTML     39K 
54: R38         Loan Payable (Details Narrative)                    HTML     22K 
55: R39         Share-Based Compensation - (Details)                HTML     60K 
56: R40         Share-Based Compensation (Details Narrative)        HTML     26K 
57: R41         Stock Issuance (Details)                            HTML     32K 
58: R42         Stock Issuance (Details Narrative))                 HTML     37K 
59: R43         Warrants (Details)                                  HTML     48K 
60: R44         Warrants (Details Narrative)                        HTML     23K 
61: R45         Business Segments (Details)                         HTML     64K 
62: R46         Business Segments (Details Narrative)               HTML     24K 
63: R47         Related-Party Transactions (Details Narrative)      HTML     29K 
64: R48         Commitments and Contingencies (Details Narrative)   HTML     30K 
66: XML         IDEA XML File -- Filing Summary                      XML    109K 
65: EXCEL       IDEA Workbook of Financial Reports                  XLSX     46K 
11: EX-101.INS  XBRL Instance -- cdxc-20160402                       XML    568K 
13: EX-101.CAL  XBRL Calculations -- cdxc-20160402_cal               XML    122K 
14: EX-101.DEF  XBRL Definitions -- cdxc-20160402_def                XML    157K 
15: EX-101.LAB  XBRL Labels -- cdxc-20160402_lab                     XML    595K 
16: EX-101.PRE  XBRL Presentations -- cdxc-20160402_pre              XML    421K 
12: EX-101.SCH  XBRL Schema -- cdxc-20160402                         XSD    117K 
67: ZIP         XBRL Zipped Folder -- 0001415889-16-005829-xbrl      Zip     64K

‘EX-10.4’ — Addendum to the Niagen Supply Agreement

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

C: C: C:

Exhibit 10.4

[*] INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION

ADDENDUM TO THE NIAGEN(TM) SUPPLY AGREEMENT BETWEEN

5LINX ENTERPRISES, INC. AND CHROMADEX, INC.

This Addendum (the “Addendum”) dated June 26, 2014 (“Addendum Effective Date”), is attached to and forms part of the NIAGEN SUPPLY AGREEMENT (the “Agreement”) dated January 3, 2014 made by and between ChromaDex, Inc., a California corporation, having a principal place of business at 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 (“Seller”) and 5Linx Enterprises, Inc., a Delaware Corporation with principal offices located at 275 Kenneth Drive, Rochester, NY 14623 (“Buyer”). To the extent that any of the terms or conditions contained in this Addendum may contradict or conflict with any of the terms or conditions of the Agreement, it is expressly understood and agreed that the terms of this Addendum shall take precedence and supersede the Agreement.

RECITALS

WHEREAS, the parties desire to amend the Agreement as provided herein;

NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the parties agree as follows:

1. Exclusivity. Buyer shall be granted exclusivity in the Territory (as defined in the Agreement) for Energy Shots industry wide until August 31, 2015. “Energy Shots” are herein defined as dietary supplements sold in a single serving asserting structure/function claims relating to energy.

2. Price for Exclusivity. As payment for Exclusivity in the Territory for Energy Shots, from Addendum Effective Date through August 31, 2015, Buyer agrees to take or pay two million dollars ($2,000,000) of the six million dollars ($6,000,000) required to be purchased in Year 2 under the Agreement.

3.	All other terms and conditions of the NIAGEN SUPPLY AGREEMENT remain the same.

4. This Addendum may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Facsimile, Portable Document Format (PDF) or photocopied signatures of the Parties will have the same legal validity as original signatures.

IN WITNESS WHEREOF, the parties have executed this Addendum by their duly authorized representatives for good and valuable consideration.

CHROMADEX, INC.

By: /s/ Troy Rhonemus

Name: Troy Rhonemus

Title: COO

Date: 6/26/2014

ELYSIUM HEALTH, INC.

By: /s/ William Faucette, Jr.

Name: William Faucette, Jr.

Title: VP North American Sales

Date: 6/16/2016

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

Filed on:	5/12/16
For Period end:	4/2/16	10-Q/A
	8/31/15	SC 13G
	6/26/14
	1/3/14	8-K, SC 13D/A
		List all Filings

↑Top

Filing Submission 0001415889-16-005829 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)